DOCSLIB.ORG

Nutrition & Dietetics SGLT2 Inhibitors (Dapagliflozin, Canagliflozin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nutrition & Dietetics SGLT2 Inhibitors (Dapagliflozin, Canagliflozin Nutrition & Dietetics SGLT2 Inhibitors (Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin) Information for patients and those close to them. This leaflet is about the medications SGLT2 Inhibitors (Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin). Please talk to your Dietitian if there is anything you don’t understand. What does this medication do? These drugs work to lower blood sugar by causing the kidneys to remove excess sugar from the body in the urine. They also help to lower blood pressure and aid weight loss. The excess sugar that is removed in the urine contains calories and over time if your calorie intake is lower than your body’s requirements you will lose weight. Who can’t take these medications? If you have Type 1 diabetes, low kidney function, are on strong water tablets or pregnant, you should not be taking this medication. How do I take this medication? You will be prescribed one tablet to take a day. Try to take it at the same time every day. If you miss a tablet and remember later on in the day you can take it. If you remember the following day, do not take two tablets together. 2 www.qegateshead.nhs.uk Do I need to be monitored? Your doctor will monitor your kidney function whilst you are taking this medication and if it drops you may be asked to stop the medication. If you develop a foot ulcer stop taking the medication and see your GP. What are the common side effects? It is normal to pass urine more often when taking this tablet and because of this you should be careful not to get dehydrated. Some people also experience urinary infections, genital thrush and constipation. Taking this medication on its own should not cause hypoglycaemia (low blood sugars) but if you are taking it with other medications such as gliclazide or insulin it may cause low blood sugars. 3 www.qegateshead.nhs.uk There is a very rare but important side effect to be aware of with this medication called diabetic ketoacidosis. If you start to feel very unwell, confused, breathing fast, thirsty and nauseated you should go to A&E and tell them you are on this drug. Cases of a rare but serious and potentially life-threatening infection (Fournier’s gangrene) have been associated with the use of SGLT-2 inhibitors. If you experience severe pain, redness of the skin, swelling or tenderness in the genital or perineal area (the perineum is the space between the anus and the scrotum in the male and between the anus and the vulva in the female) along with fever or generally feeling unwell, you should seek URGENT medical attention mentioning that you have been on SGLT-2 treatment that will need stopping if Fournier’s gangrene is suspected. 4 www.qegateshead.nhs.uk Are there any sick day rules? If you are unable to eat and drink due to vomiting or nausea you should stop this medication until you are able to eat and drink again. What about driving? You do not need to inform the DVLA if you are on this medication unless any of the following applies to you; • You have problems with vision in both eyes, or in the remaining eye if you have sight in one eye only. • You develop any problems with the circulation, or sensation in your legs or feet which makes it necessary for you to drive certain types of vehicles only, for example automatic vehicles, or vehicles with a hand operated accelerator or brake. This must be shown on your driving licence. 5 www.qegateshead.nhs.uk What about driving? You need laser treatment to both eyes or in the remaining eye if you have sight in one eye only. You need to notify the DVLA if you hold a Group 2 licence and are taking this medication. If you have any questions about this medication, contact your GP. Use this space to write down any questions that you may want to discuss. 6 www.qegateshead.nhs.uk Use this space to write down any questions that you may want to discuss. Data Protection Any personal information is kept confidential. There may be occasions where your information needs to be shared with other care professionals to ensure you receive the best care possible. In order to assist us to improve the services available, your information may be used for clinical audit, research, teaching and anonymised for National NHS Reviews and Statistics. Further information is available via Gateshead Health NHS Foundation Trust website (https://www.qegateshead.nhs.uk/fairprocessing) or by contacting the Data Protection Officer by telephone on 0191 445 8418 or by email [email protected]. This leaflet can be made available in other languages and formats upon request No. ER36 Version: 1 First Published: 08/2020 Review Date: 08/2022 Author: Robyn Collery 7 www.qegateshead.nhs.uk .
Load more

Recommended publications
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • Step Therapy
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2020 P 3086-9 Program Step Therapy – Diabetes Medications - SGLT2 Inhibitors Medication Farxiga (dapagliflozin)*, Glyxambi (empagliflozin/linagliptan), Invokana (canagliflozin)*, Invokamet (canagliflozin/metformin)*, Invokamet XR (canaglifloxin/metformin extended-release)*, Jardiance (empagliflozin), Qtern (dapagliflozin/saxagliptin)*, Segluromet (ertugliflozin/metformin)*, Steglatro (ertugliflozin)*, Steglujan (ertugliflozin/sitagliptin)*, Xigduo XR (dapagliflozin/metformin extended-release)* P&T Approval Date 10/2016, 10/2017, 4/2018, 8/2018, 12/2018, 2/2019, 2/2020, 5/2020; 7/2020 Effective Date 10/1/2020; Oxford only: 10/1/2020 1. Background: Farxiga (dapagliflozin)*, Invokana (canagliflozin)*, Jardiance (empagliflozin) and Steglatro (ertugliflozin)* are sodium-glucose co-transporter 2 (SGLT2) inhibitors indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Farxiga*, Invokana* and Jardiance have additional indications. Farxiga* is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction. Invokana* is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD), and to reduce the risk of end-stage kidney disease (ESKD), doubling of
    [Show full text]
  • The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves B-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat
    1521-0103/350/3/657–664$25.00 http://dx.doi.org/10.1124/jpet.114.213454 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 350:657–664, September 2014 Copyright ª 2014 by The American Society for Pharmacology and Experimental Therapeutics The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves b-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat Henrik H. Hansen, Jacob Jelsing, Carl Frederik Hansen, Gitte Hansen, Niels Vrang, Michael Mark, Thomas Klein, and Eric Mayoux Gubra, Hørsholm, Denmark (H.H.H., J.J., C.F.H., G.H., N.V.); and Boehringer Ingelheim Pharma, Biberach, Germany (M.M., T.K., E.M.) Received January 22, 2014; accepted July 2, 2014 Downloaded from ABSTRACT Type 2 diabetes is characterized by impaired b-cell function at week 8 of treatment compared with week 4, those of empagliflozin associated with progressive reduction of insulin secretion and remained stable throughout the study period. Similarly, empagliflozin b -cell mass. Evidently, there is an unmet need for treatments improved glucose tolerance and preserved insulin secretion jpet.aspetjournals.org with greater sustainability in b-cell protection and antidiabetic after both 4 and 8 weeks of treatment. These effects were efficacy. Through an insulin and b cell–independent mechanism, reflected by less reduction in b-cell mass with empagliflozin or empagliflozin, a specific sodium glucose cotransporter type 2 liraglutide at week 4, whereas only empagliflozin showed b-cell (SGLT-2) inhibitor, may potentially provide longer efficacy. This sparing effects also at week 8. Although this study cannot be study compared the antidiabetic durability of empagliflozin treat- used to dissociate the absolute antidiabetic efficacy among ment (10 mg/kg p.o.) against glibenclamide (3 mg/kg p.o.) and the different mechanisms of drug action, the study demon- liraglutide (0.2 mg/kg s.c.) on deficient glucose homeostasis and strates that empagliflozin exerts a more sustained improve- b-cell function in Zucker diabetic fatty (ZDF) rats.
    [Show full text]
  • PRESCRIBING INFORMATION ------WARNINGS and PRECAUTIONS------These Highlights Do Not Include All the Information Needed to Use JARDIANCE Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for Ketoacidosis: Assess patients who present with signs and symptoms of JARDIANCE. metabolic acidosis for ketoacidosis, regardless of blood glucose level. If suspected, discontinue JARDIANCE, evaluate and treat promptly. JARDIANCE® (empagliflozin tablets), for oral use Before initiating JARDIANCE, consider risk factors for ketoacidosis. Initial U.S. Approval: 2014 Patients on JARDIANCE may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ---------------------------RECENT MAJOR CHANGES--------------------------- ketoacidosis. (5.1) Volume Depletion: Before initiating JARDIANCE, assess volume status Indications and Usage (1) 8/2021 and renal function in patients with impaired renal function, elderly Dosage and Administration (2.1) 6/2021 patients, or patients on loop diuretics. Monitor for signs and symptoms Dosage and Administration (2.2) 8/2021 during therapy. (5.2, 6.1) Dosage and Administration (2.3) – Removed 8/2021 Urosepsis and Pyelonephritis: Evaluate patients for signs and symptoms Contraindications (4) 6/2021 of urinary tract infections and treat promptly, if indicated (5.3) Warnings and Precautions (5.1, 5.2) 6/2021 Hypoglycemia: Consider lowering the dose of insulin secretagogue or Warnings and Precautions (5.3, 5.5) 8/2021 insulin to reduce the risk of hypoglycemia when initiating JARDIANCE Warnings and Precautions (5.9) – Removed 6/2021 (5.4) ----------------------------INDICATIONS AND USAGE--------------------------- Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Serious, JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor life-threatening cases have occurred in both females and males.
    [Show full text]
  • Clinical Pharmacology Biopharmaceutics Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206111Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) (b) Q=(4) % at 20 minutes for empagliflozin and metformin HCl Review: The Biopharmaceutics review is focused on the evaluation and acceptability of the bioequivalence and dissolution data to support approvability of the proposed FDC tablets. RECOMMENDATION: The bioequivalence results and dissolution method are acceptable. From the Biopharmaceutics perspective, NDA 206111 for Empagliflozin/Metformin Hydrochloride Fixed Dose Combination Tablets is recommended for approval. Signature Signature Digitally signed by Kelly M. Kitchens -S Digitally signed by Tapash K. Ghosh -S DN: c=US, o=U.S. Government, DN: c=US, o=U.S. Government, ou=HHS, Kelly M. Tapash K. ou=FDA, ou=People, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=200033657 0.9.2342.19200300.100.1.1=1300148262 , cn=Tapash K. Ghosh -S 4, cn=Kelly M. Kitchens -S Date: 2015.04.15 16:19:26 -04'00' Kitchens -S Date: 2015.04.15 15:55:42 -04'00' Ghosh -S Kelly M. Kitchens, Ph.D. Tapash Ghosh, Ph.D. Acting Biopharmaceutics Lead Acting Biopharmaceutics Branch Chief Office of New Drug Products Office of New Drug Products cc. PSeo. 4 Bioequivalence Study No. 1276.6 8 9 Bioanalytical Results: Analyte Name: Empagliflozin Parameter Standard Curve Samples Concentration (nmol/mL) 1.11 2.22 111 55.4 222 665 998 1110 Inter day Precision 7.5 5.2 2.8 2.3 2.2 2.2 2.6 1.7 (%CV) Inter day Accuracy -0.8 0.6 1.0 0.3 -1.7 0.4 -0.2 0.1 (%bias) Linearity 0.994576 – 0.999437 (range
    [Show full text]
  • SGLT2) Inhibitors (Gliflozins) in Adults with Type 2 Diabetes (T2DM
    Sodium-glucose cotransporter-2 (SGLT2) inhibitors (Gliflozins) in Adults with Type 2 Diabetes (T2DM) There are currently four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ertugliflozin) licensed in the UK for the management of adults with T2DM. No head to head trials between the SGLT2 inhibitors have been conducted. As at December 2019, clinical outcome data is available for three of the four SGLT2 inhibitors around their cardiovascular effects in people with T2DM. Ertugliflozin is still to report on this data. This document summarises the key prescribing considerations. NICE Technology Appraisal Recommendation NICE makes recommendations for when SGLT2 inhibitors can be considered in adults with T2DM; Hertfordshire Medicines Management Committee Recommendations are in line with NICE guidance: Monotherapy NICE TA 390: Canagliflozin, Dapagliflozin and Empagliflozin and NICE TA 572: Ertugliflozin as monotherapies for treating T2DM Monotherapy recommended as option in adults for whom metformin is contraindicated or not tolerated and when diet & exercise alone do not provide adequate glycaemic control, only if: •a DPP‑4 inhibitor would otherwise be prescribed and •a sulfonylurea or pioglitazone is not appropriate. Dual therapy NICE TA 315: Canagliflozin, NICE TA288: Dapagliflozin, TA 336: Empagliflozin, TA 572: Ertugliflozin as combination therapies for treating T2DM In a dual therapy regimen in combination with metformin is recommended as an option, only if: •a sulfonylurea is contraindicated or not tolerated or •the person is at significant risk of hypoglycaemia or its consequences. In combination with insulin NICE TA 315: Canagliflozin, NICE TA288: Dapagliflozin, TA 336: Empagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option.
    [Show full text]
  • 204629Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204629Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Office of Medication Error Prevention and Risk Management Risk Evaluation and Mitigation Strategy (REMS) Review Date: July 28, 2014 Reviewer(s): Amarilys Vega, M.D., M.P.H, Medical Officer Division of Risk Management (DRISK) Team Leader: Doris Auth, Pharm.D, Team Leader DRISK Division Director Cynthia LaCivita, Pharm.D, Acting Director DRISK Subject: Evaluation of need for a REMS Drug Name(s): Empagliflozin (Jardiance®) Therapeutic Class: Sodium-dependent glucose co-transporter-2 (SGLT2) inhibitor Dosage and Route: 10 mg, 25 mg tablet once daily/oral Application Type/Number: NDA 204629 Submission Number: Resubmission, June 3, 2014 (0032) Applicant/sponsor: Boehringer Ingelheim Pharmaceuticals, Inc. OSE RCM #: 2013-619 and 2013-656 *** This document contains proprietary and confidential information *** that should not be released to the public Reference ID: 3600276 1 INTRODUCTION This review documents the Division of Risk Management’s (DRISK) evaluation of whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary for empagliflozin (NDA 204629). Boehringer Ingelheim Pharmaceuticals, Inc. is seeking approval for empagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). DRISK reviewed the original application for empagliflozin submitted to FDA on March 5, 2013 and determined that a REMS was not required to manage the serious risks associated to empagliflozin (e.g., hypoglycemia, volume depletion, and genital infections).
    [Show full text]
  • ANTI-HYPERGLYCEMIC DIABETES AGENTS in T2DM: Color Outcomes Comparison Summary Table
    ANTI-HYPERGLYCEMIC DIABETES AGENTS in T2DM: Outcomes Comparison Summary Table L Regier BSP BA, M LeBras PharmD, T Trischuk PharmD, J Bareham BSP, L Lu BSP © www.RxFiles.ca Aug 2021 Drug Class Sulfonylureas TZDs Meglitinides DPP4 Inhibitors GLP1 Agonists *** SGLT2 Inhibitors *** Insulin in T2DM Generic Metformin Gliclazide Glyburide Pioglitazone Rosiglitazone Acarbose Repaglinide Saxagliptin ONGLYZA Liraglutide VICTOZA Empagliflozin JARDIANCE Intensity: Intensity: BRAND (MF) DIAMICRON DIABETA ACTOS, g AVANDIA GLUCOBAY GLUCONORM Sitagliptin JANUVIA Exenatide BYETTA, BYDUREON Canagliflozin INVOKANA Less More GLUCOPHAGE Dulaglutide TRULICITY Dapagliflozin FORXIGA, FARXIGA Alogliptin NESINA (e.g. NPH (Multiple daily GLUCOTROL D/C STEGLATRO Glipizide Nateglinide Semaglutide OZEMPIC, RYBELSUS (PO) Ertugliflozin Linagliptin TRAJENTA HS + MF) doses) STARLIX D/C SPREAD-DIMCAD] Lixisenatide ADLYXINE; ALBIGLUTIDE D/C SAVOR-TIMI 53, EMPA-REG, CANVAS, CREDENCE, T2DM: UKPDS-33,80; ADVANCE, Major trials to UKPDS- ProACTIVE ACE 33,34,80 UKPDS- Meta-analysis. TECOS, EXAMINE LEADER, EXSCEL, FREEDOM CVO, DECLARE, VERTIS-CV (2020), ACCORD, VADT, ORIGIN, DEVOTE support ADVANCE (Prevention (ADOPT; 33,80 Ferwana M. Meta- RECORD interim, PROLOGUE, REWIND, SUSTAIN-6, PIONEER-6, DAPA-HF, DAPA-CKD (2020), T1DM: DCCT/EDIC findings/ analysis 2013. trial: Stop- - some use in (ADOPT) ADOPT, DREAM CARMELINA, EMPEROR-Reduced & -Preserved (Also Boussageon et al. Meta- Outcomes* ADVANCE) SR-Liao 2017; IRIS NIDDM) ELIXA, HARMONY CAROLINA (2020), EMPA-Kidney (2022) analysis.
    [Show full text]
  • Cost-Effectiveness of Empagliflozin Versus Canagliflozin, Dapagliflozin
    Emerging technologies, pharmacology and therapeutics Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2020-001313 on 3 May 2021. Downloaded from Cost-­effectiveness­of­empagliflozin­ versus­canagliflozin,­dapagliflozin,­or­ standard­of­care­in­patients­with­type­2­ diabetes­and­established­ cardiovascular­disease Odette S Reifsnider ,1 Anuraag R Kansal,1 Pranav K Gandhi,2 Lael Cragin,1 Sarah B Brand,1 Egon Pfarr,3 Kyle Fahrbach,4 Anastasia Ustyugova3 To cite: Reifsnider OS, ABSTRACT Kansal AR, Gandhi PK, Introduction Empagliflozin, a sodium- glucose co- Significance of this study et al. Cost- effectiveness transporter-2 (SGLT-2) inhibitor, is approved in the USA of empagliflozin versus to reduce risk of cardiovascular (CV) death in adults What is already known about this subject? canagliflozin, dapagliflozin, with type 2 diabetes mellitus (T2DM) and established CV ► The sodium glucose co- transporter-2 inhibitor (SGLT- or standard of care in 2) empagliflozin is Food and Drug Administration patients with type 2 disease, based on EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes (FDA) approved to reduce the risk of cardiovascular diabetes and established (CV) death in adults with type 2 diabetes mellitus cardiovascular disease. Mellitus Patients) trial results. Empagliflozin reduced major (T2DM) and established CV disease (CVD) based BMJ Open Diab Res Care adverse CV event (MACE) by 14%, CV death by 38%, and 2021;9:e001313. doi:10.1136/ hospitalization for heart failure (HHF) by 35% vs placebo, on the EMPA- REG OUTCOME trial, which showed a bmjdrc-2020-001313 each on top of standard of care (SoC).
    [Show full text]
  • Management of Type 2 Diabetes Mellitus Dr Naomi Achong Endocrinologist MBBS(Hons) Bsc FRACP Phd Overview
    Management of Type 2 Diabetes Mellitus Dr Naomi Achong Endocrinologist MBBS(Hons) BSc FRACP PhD Overview • Overview of T2DM & glycaemic targets • Treatment after metformin – newer agents on the market • SGLT2 inhibitors • DPP4 agonists • GLP1 antagonists • Insulin options • Newer options – coformulation Diagnosis • ADS position statement • Criteria: • HbA1c > 6.5% • Fasting glucose > 7mmol/L. • Random glucose > 11.1mmol/L • GTT showing fasting > 7 or 2hr > 11.1mmol/L • Patients with IGT have an increased risk of death and vascular disease (regardless of progression to diabetes) as well as microvascular complications • Risk of progression to T2DM is reduced by 58% with lifestyle modification and 31% with metformin 1.The DECODE Study. Arch Intern Med 2001; 161:397-405 2. Singleton JR et al. Diabetes 2003;52(12):2867-2873 3. Diabetes Prevention Program Research Group. N Engl J Med 2002; 346:393-403 Optimising health outcomes in diabetes • Glucose control • Smoking cessation • Blood pressure control • Lipid management with priority to statins • Some circumstances, antiplatelet therapy ADA/EASD – 2015 position statement • Glycaemic targets need to be individualised • Based on modifiable and non-modifiable factors 1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M. et al Diabetologia. 2015; 58: 429-442 1. Inzucchi S.E. et al. Diabetologia. 2015; 58: 429-442 Importance of glycaemic control GOOD GLYCAEMIC CONTROL Reduces diabetes-related complications Reduces total diabetes-related costs UKPDS1 Retrospective database analysis2 1% mean HbA1c reduction results in: HbA1c ≤7% continuously for 1 year results in . 37% 14% 21% 25% Which included: Myocardial 22% lower diabetes infarction medical costs Diabetes-related 28% lower diabetes mortality Diabetes-related pharmacy costs treatment costs Microvascular complications .
    [Show full text]
  • The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates
    2784 Diabetes Volume 65, September 2016 Simon A. Hawley,1 Rebecca J. Ford,2 Brennan K. Smith,2 Graeme J. Gowans,1 Sarah J. Mancini,3 Ryan D. Pitt,2 Emily A. Day,2 Ian P. Salt,3 Gregory R. Steinberg,2 and D. Grahame Hardie1 The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels Diabetes 2016;65:2784–2794 | DOI: 10.2337/db16-0058 Canagliflozin, dapagliflozin, and empagliflozin, all recently transporters that carry glucose across apical membranes approved for treatment of type 2 diabetes, were derived of polarized epithelial cells against concentration gradi- from the natural product phlorizin. They reduce hypergly- ents, driven by Na+ gradients. SGLT1 is expressed in the cemia by inhibiting glucose reuptake by sodium/glucose small intestine and responsible for most glucose uptake cotransporter (SGLT) 2 in the kidney, without affecting across the brush border membrane of enterocytes, whereas intestinal glucose uptake by SGLT1. We now report that SGLT2 is expressed in the kidney and responsible for most fl canagli ozin also activates AMPK, an effect also seen glucose readsorption in the convoluted proximal tubules. with phloretin (the aglycone breakdown product of The first identified SGLT inhibitor was a natural product, fi phlorizin), but not to any signi cant extent with dapagli- phlorizin, which is broken down in the small intestine to flozin, empagliflozin, or phlorizin. AMPK activation oc- phloretin, the aglycone form (Fig. 1). Although phlorizin curred at canagliflozin concentrations measured in had beneficial effects in hyperglycemic animals (2), it in- human plasma in clinical trials and was caused by hibits SGLT1 and SGLT2, causing adverse gastrointestinal inhibition of Complex I of the respiratory chain, leading effects (3).
    [Show full text]
  • JARDIANCE (Empagliflozin)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Ketoacidosis: Assess patients who present with signs and symptoms of These highlights do not include all the information needed to use metabolic acidosis for ketoacidosis, regardless of blood glucose level. If JARDIANCE safely and effectively. See full prescribing information for suspected, discontinue JARDIANCE, evaluate and treat promptly. JARDIANCE. Before initiating JARDIANCE, consider risk factors for ketoacidosis. Patients on JARDIANCE may require monitoring and temporary JARDIANCE® (empagliflozin) tablets, for oral use discontinuation of therapy in clinical situations known to predispose to Initial U.S. Approval: 2014 ketoacidosis. (5.2) • Acute kidney injury and impairment in renal function: Consider ---------------------------RECENT MAJOR CHANGES--------------------------- temporarily discontinuing in settings of reduced oral intake or fluid Indications and Usage (1) 12/2016 losses. If acute kidney injury occurs, discontinue and promptly treat. Warnings and Precautions (5) 12/2016 Monitor renal function during therapy. (5.3) • Urosepsis and Pyelonephritis: Evaluate patients for signs and symptoms ----------------------------INDICATIONS AND USAGE--------------------------­ of urinary tract infections and treat promptly, if indicated (5.4) JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor • Hypoglycemia: Consider lowering the dose of insulin secretagogue or indicated: insulin to reduce the risk of hypoglycemia when initiating JARDIANCE • as an adjunct to diet and exercise to
    [Show full text]